Expanded access programmes: patient interests versus clinical trial integrity.
Authors
Lorigan, Paul CAscierto, P
Dummer, R
Eggermont, A
Flaherty, K
Garbe, C
Gogas, H
Hauschild, A
Kefford, R
Kirkwood, J
Larkin, J
Long, G
Maio, M
McArthur, G
Ribas, A
Robert, C
Schadendorf, D
Sondak, V
Wolchok, J
Hudson, Andrew M
Affiliation
University of Manchester/The Christie NHS Foundation Trust, Manchester, UKIssue Date
2015-01
Metadata
Show full item recordCitation
Expanded access programmes: patient interests versus clinical trial integrity. 2015, 16 (1):15-7 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(14)71161-1PubMed ID
25638540Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(14)71161-1
Scopus Count
Collections
Related articles
- Dilemmas in the compassionate supply of investigational cancer drugs.
- Authors: Lewis JR, Lipworth W, Kerridge I, Doran E
- Issue date: 2014 Sep
- Situating the trovan trial with the use of experimental ebola therapies is like comparing an apple with an orange.
- Authors: Afolabi MO
- Issue date: 2015 Mar
- Ebola, ethics, and the question of culture.
- Authors: Komesaroff P, Kerridge I
- Issue date: 2014 Dec
- Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges.
- Authors: Hyun I
- Issue date: 2010 Summer
- On Patient Safety: A Right to Try, Not Exploit.
- Authors: Rickert J
- Issue date: 2021 Jul 1